Company intelligence / Profile preview

Anhui HygeianCells BioMedical

Ownership: Private
Development stage: Other

Overview

Anhui HygeianCells BioMedical is a private Chinese biotech company founded in 2019, developing at least one clinical-stage asset (EE-001) for heart failure currently in early Phase 1 trials as of April 2025. The company also holds patents related to therapies for macrophage-mediated diseases, enteritis, and intestinal cancer. No detailed clinical results are publicly available yet.[1][2][4]

Therapeutic areas: ImmunologyGastroenterologyCardiovascular
Modalities: Unknown (insufficient public data to specify; likely Small molecule or Biologic based on typical early-stage biotech focus)
Industry: Biotech

Drug pipeline

1 asset

EE001

Partnerships

No major partnerships disclosed as of April 2025.[4]

Beyond the preview

Go deeper on Anhui HygeianCells BioMedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anhui HygeianCells BioMedical.

Explore the full profile